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introduction: Atrial fibrillation (AF) is associated with up to 20% of ischemic strokes with anticoagulation remains the cornerstone of treatment. 
The left atrial appendage (LAA) is the main source of thromboemboli. Recent studies demonstrated that mechanical closure of the LAA is an effective 
strategy to thromboprophylaxis. Long-term antiplatelet therapy is recommended to prevent thrombus formation post device insertion. We wish to 
determine the efficacy of an antiplatelet strategy in preventing thrombus formation, and the role for periprocedural anticoagulation.
methods: Thirty-five patients (27 men, 8 women; mean age 74.5 ± 8.2years) with nonvalvular AF, at high risk for cardioembolic stroke (mean 
CHA2DS2VASc score 3.6±1.8) and complications of oral anticoagulation, underwent percutaneous LAA closure using the WATCHMAN device with 
fluoroscopy and transoesophageal echocardiography (TOE) guidance. Follow-up included clinical and echocardiographic review within 45 days.
results: The LAA was successfully occluded in 31 patients (97.1%). Four cases were abandoned due to unsuitable appendage anatomy. Post 
WATCHMAN insertion, 26 patients were commenced on warfarin therapy. Due to significant anticoagulation contraindications, five patients were 
commenced on dual antiplatelet therapy (DAPT) - aspirin 75mg and clopidogrel 75mg. The six-week follow up TOE demonstrated mobile thrombus 
on the atrial side of the device in four patients treated with DAPT. These patients were therefore commenced on full anticoagulation. Subsequent 
TOE demonstrated full resolution of the thrombus in all patients. In one patient, there was evidence of flow within the device indicating failure to 
endothelialize. No thrombus was demonstrated in the patients who received warfarin or dabigatran anticoagulation.
conclusion: Our experience revealead that while LAA occlusion is a safe and sucessful procedure. However, the practice of DAPT alone before 
endothelisation of the device, is insufficient in preventing device-related thrombus formation. We suggest that full anticoagulation should be 
undertaken for the first three months following implantation.
